According to a major international study, Switzerland has once again fallen behind other European countries in terms of access to new innovative medicines – from sixth to seventh place. Particularly worrying is the fact that, compared to Germany, only around half as many new innovative medicines are reimbursed as standard via the specialty list.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Eosinophils in the Blood in COPD
How many measurements are needed to be sure?
- From symptom to diagnosis
Abdominal Pain – Von Meyenburg Complexes of the Liver
- Multiple sclerosis
Physical and psychosocial fatigue have the greatest impact on HRQoL
- Congenital Vascular Malformations
Personalized Treatment Before a Planned Pregnancy
- Hyperhidrosis: Keep a Cool Head
An Overview of Important Treatment Options
- This article was sponsored by Johnson & Johnson.
Give your patients a chance to live longer without progression with TECVAYLI® + DARZALEX® compared to DPd/DVd1
- Sjögren's Syndrome in Early Childhood
Children often develop lymphomas
- 2026 Vaccination Schedule: Important Changes